NOVARTIS AG (NVS) — Congressional Stock Trades & Intelligence
NOVARTIS AG (NVS) is an active recipient of U.S. federal and defense procurement awards. According to federal procurement records and obligation filings, the company has been awarded 0 prime federal contracts and delivery orders totaling approximately $0 across 1 federal awarding agencies, with the most recent award action registered on —.
Federal contracts represent substantial multi-year revenue visibility for prime contractors and defense suppliers. Gemral Edge continuously reconciles federal award obligations from the Federal Procurement Data System (FPDS) and USAspending with congressional disclosures, tracking capital flow from policy authorization through corporate execution.
Quick Facts & Defense Contracting Direct Answers
How much does NOVARTIS AG receive in federal government contracts?
NOVARTIS AG has been awarded over $0 in tracked prime federal obligations across 1 awarding agencies, as recorded in official FPDS and USAspending data.
Which congressional lawmakers trade NOVARTIS AG (NVS) stock?
Public Periodic Transaction Reports (PTR) under the STOCK Act record transactions in NOVARTIS AG (NVS) by members of Congress including Daniel S Goldman, Lisa C Mcclain, George Whitesides.
How are federal defense contracts mapped to NOVARTIS AG on Gemral Edge?
Gemral Edge programmatically reconciles prime award obligations from SAM.gov, USAspending, and FPDS through corporate parent CAGE and UEI hierarchies directly to ticker NVS.
Unified Ticker Intelligence Dossier (NVS)
Synthesis: Mã NVS ghi nhận dữ liệu hoạt động tổng hợp qua các kênh công quyền và dòng tiền.
Temporal Context: Ghi nhận sự kiện và luồng thông tin mới trong 365 ngày qua đối với NVS.
Data Coverage & Verification: Overall coverage score: 50% across 6 pillars (Government, Policy, Flow, Management, Catalysts, Historical). Verified by 2 independent statutory data sources.
Congressional Stock Trading Activity in NVS
Disclosed stock purchases and sales by members of Congress and spouses involving NOVARTIS AG securities under the STOCK Act:
| Lawmaker | Party-State | Chamber | Transaction Date | Action | Disclosed Range | Est. Return |
|---|---|---|---|---|---|---|
| Lisa C. McClain | R-MI | HOUSE | 2025-10-30 | BUY | $1K – $15K | +12.1% |
| Lisa C. McClain | R-MI | HOUSE | 2025-06-11 | BUY | $1K – $15K | +16.4% |
| George Whitesides | D-CA | HOUSE | 2025-03-24 | SELL | $100K – $250K | +23.8% |
| Daniel S. Goldman | D-NY | HOUSE | 2023-07-10 | SELL | $50K – $100K | +42.4% |
| Daniel S. Goldman | D-NY | HOUSE | 2023-03-31 | BUY | $50K – $100K | +49.4% |
| Alan S. Lowenthal | D-CA | HOUSE | 2020-11-23 | SELL | $1K – $15K | +57.5% |
| Alan S. Lowenthal | D-CA | HOUSE | 2020-11-23 | SELL | $15K – $50K | +57.5% |
| Kevin Hern | R-OK | HOUSE | 2020-07-27 | BUY | $1K – $15K | +62.3% |
| Greg Gianforte | R-MT | HOUSE | 2020-03-18 | BUY | $1K – $15K | +83.4% |
| Mikie Sherrill | D-NJ | HOUSE | 2020-02-20 | SELL | $1K – $15K | +42.8% |
| Mikie Sherrill | D-NJ | HOUSE | 2019-05-28 | SELL | $1K – $15K | +58.2% |
| John H. Rutherford | R-FL | HOUSE | 2019-04-18 | BUY | $1K – $15K | +79.9% |
| Alan S. Lowenthal | D-CA | HOUSE | 2019-02-15 | BUY | $896 – $59 | +70.7% |
| Alan S. Lowenthal | D-CA | HOUSE | 2019-02-15 | BUY | $268 – $98 | +70.7% |
| Alan S. Lowenthal | D-CA | HOUSE | 2019-02-15 | BUY | $1K – $15K | +70.7% |
Related Congressional Committees & Active Lawmakers
Disclosed lawmakers and congressional committees holding policy jurisdiction, defense appropriations oversight, or direct capital exposure in NVS:
- Lisa C. McClain (House) — Disclosed STOCK Act transactions (R-MI)
- George Whitesides (House) — Disclosed STOCK Act transactions (D-CA)
- Daniel S. Goldman (House) — Disclosed STOCK Act transactions (D-NY)
- Alan S. Lowenthal (House) — Disclosed STOCK Act transactions (D-CA)
- Kevin Hern (House) — Disclosed STOCK Act transactions (R-OK)
- Greg Gianforte (House) — Disclosed STOCK Act transactions (R-MT)
- Mikie Sherrill (House) — Disclosed STOCK Act transactions (D-NJ)
- John H. Rutherford (House) — Disclosed STOCK Act transactions (R-FL)
Latest Real-Time Intelligence & Breaking Events
Live contract obligations, SEC filings, and procurement intelligence for NOVARTIS AG are monitored 24/7 on Gemral Edge Breaking News and Defense Radar.
Federal Contracting Dynamics & Government Revenue Exposure
Government contracting for defense and enterprise infrastructure follows strict Federal Acquisition Regulation (FAR) guidelines, often spanning multi-year base periods with optional extension years. Monitoring prime contractor award velocity provides institutional investors and market participants with un-lagged visibility into backlog expansion, agency budget priorities, and defense authorization funding flows.
Furthermore, when members of congressional defense, intelligence, or appropriations committees disclose trading activity in major federal contractors such as NOVARTIS AG, cross-referencing contract award timelines with legislative disclosures highlights important intersections of public policy and corporate performance.
Frequently asked questions
How much does NOVARTIS AG receive in federal government contracts?
NOVARTIS AG holds over $0 in tracked federal obligations across 1 public agencies, providing multi-year revenue visibility across defense and civilian procurement budgets.
Which congressional lawmakers trade NOVARTIS AG (NVS) stock?
NOVARTIS AG (NVS) stock transactions have been disclosed by members of Congress including Daniel S Goldman, Lisa C Mcclain, George Whitesides. Disclosures filed under the STOCK Act detail execution dates, asset classes, and statutory valuation ranges.
How are federal defense contracts resolved to NOVARTIS AG?
Gemral Edge maps prime award notices from the Federal Procurement Data System (FPDS) and USAspending through Ultimate Parent CAGE and UEI corporate hierarchies directly to parent ticker NVS.
What technology stack signals are detected for NOVARTIS AG?
Active talent hiring requisitions and engineering role profiles are continuously monitored across public corporate job postings to track enterprise software adoption and technology migration patterns.
Data intelligence from public filings — not investment advice.